The simultaneous emergence of the best and the worst stocks makes the fund’s position on the medical track a double day of ice and fire.
Affected by the covid-19 epidemic, a number of stocks in the medical track had significant stock price changes driven by events, including fund heavy position stocks Xi’An International Medical Investment Company Limited(000516) and fund unique stocks Andon Health Co.Ltd(002432) . The Chinese reporter of securities times · securities firm noted that a number of fund companies have reduced the valuation of Xi’An International Medical Investment Company Limited(000516) to 7.11 yuan, which means that the fund’s heavy position stocks will face no small room for decline. When the fund’s heavy position stocks Xi’An International Medical Investment Company Limited(000516) were severely reduced by the fund, a mini fund company or its unique stocks earned a profit of 1.3 billion yuan in three months.
Xi’An International Medical Investment Company Limited(000516) was downgraded by several funds
Affected by the suspension of business for rectification and stock st, several funds announced a reduction in Xi’An International Medical Investment Company Limited(000516) valuation over the weekend.
CITIC Prudential fund disclosed at the weekend that, according to relevant regulations and through consultation with the fund custodian, the fund company decided to value the ” Xi’An International Medical Investment Company Limited(000516) ” (securities code 000516) held by its securities investment fund at RMB 7.18/share from January 14, 2022.
The above-mentioned funds said that they would pay close attention to the follow-up developments of ” Xi’An International Medical Investment Company Limited(000516) ” and adjust their valuation price in time if necessary. From the date when the above stock transactions reflect the trading characteristics of the active market, the company will comprehensively refer to various relevant influencing factors and negotiate with the fund custodian to determine to resume using the closing price of the day for valuation, and no further announcement will be made at that time.
Compared with the valuation of 7.18 yuan, Jinying fund adjusted the valuation of Xi’An International Medical Investment Company Limited(000516) lower. On the same day, Jinying Fund announced that according to the Xi’An International Medical Investment Company Limited(000516) suggestive public notice on other risks warning and suspension of company shares issued on Xi’An International Medical Investment Company Limited(000516) January 13, 2022, in order to make the valuation of relevant funds under the fund manager fair and reasonable, From January 14, 2022, the fund manager revalued Xi’An International Medical Investment Company Limited(000516) (Code: 000516) held by its securities investment fund, and the valuation price was adjusted to RMB 7.11.
Before the announcement, the closing price of Xi’An International Medical Investment Company Limited(000516) was 8.37 yuan as of January 13, and the lowest valuation adjustment of 7.11 yuan means that the fund company expects the stock to fall another 15%. In addition to Golden Eagle Fund and CITIC Prudential fund, GF fund and BOC fund with a position of Xi’An International Medical Investment Company Limited(000516) also issued relevant announcements earlier, and the valuation price adjustment of Xi’An International Medical Investment Company Limited(000516) was 7.11 yuan.
assisted reproduction is fierce, and the boss did not buy after investigation
At present, only four public offerings with positions of Xi’An International Medical Investment Company Limited(000516) have issued valuation reduction announcements, but other companies with positions in the stock may follow up and reduce the valuation of Xi’An International Medical Investment Company Limited(000516) in the future. According to the periodic report disclosed by Xi’An International Medical Investment Company Limited(000516) , as of the end of the third quarter of last year, 22 funds under nine public offerings held Xi’An International Medical Investment Company Limited(000516) 132 million shares, with a market value of 1.498 billion yuan, accounting for about 7% of the circulating shares.
The Chinese reporter of securities firm noted that as a star company in the field of assisted reproduction, Xi’An International Medical Investment Company Limited(000516) has always attracted financial attention. In the first quarter of last year, they obtained the research of top flow fund managers Zhou Yingbo and Zhang Kun. However, according to the disclosed position information, the two top flow public offerings seem to have nothing to do with Xi’An International Medical Investment Company Limited(000516) after the research.
The inherent meaning of fund research usually also includes the research on the competitors of position varieties. Related to this, when Zhang Kun investigated Xi’An International Medical Investment Company Limited(000516) in the first quarter of last year, the e-fund high-quality enterprise fund he managed was listing Jinxin reproduction of Hong Kong stocks as the core heavy position variety at that time, and the stock was forming a competitive relationship with Xi’An International Medical Investment Company Limited(000516) .
However, according to the disclosed positions of the fund, even Jinxin reproductive, which has better performance and lower valuation, has faded out of the list of the top ten heavy positions of Zhang Kun fund, which is not good news for Xi’An International Medical Investment Company Limited(000516) .
earn 1.3 billion in three months. Is the mini fund satisfied with this 10x stock?
Just when Xi’An International Medical Investment Company Limited(000516) was downgraded by the fund, Andon Health Co.Ltd(002432) recently enjoyed four consecutive days of trading, which made the stock rise more than ten times in less than three months.
After the share price soared tenfold in a short time, Andon Health Co.Ltd(002432) recently announced that its U.S. subsidiary ihealth labs Inc and ACC (U.S. Army contracting command) signed a procurement contract on January 13, 2022 local time and came into force.
According to the contents of the contract, the total amount of contract price and tax is as high as US $1.275 billion, or 8.102 billion yuan. This figure far exceeds Andon Health Co.Ltd(002432) the revenue level of 790 million yuan in the first three quarters of 2021 and significantly exceeds its revenue in 2020. According to the disclosure, ACC of the United States represents HHS of the United States, which is an administrative department of the U.S. federal government serving the health field, that is, the largest health security agency of the U.S. federal government.
The Chinese reporter of the securities firm noted that Andon Health Co.Ltd(002432) is a typical unique fund stock. According to the disclosed information of the stock, as of the end of the third quarter of last year, only one fund company appeared on the list of the top ten shareholders of the stock. A special account of Beixin Ruifeng fund company held Andon Health Co.Ltd(002432) 1971 million shares by the end of the reporting period, accounting for 4.12% of the total share capital, Beixin Ruifeng fund is the second largest shareholder of the stock.
Based on the closing price of 6.69 yuan at the end of the third quarter of last year when Beixin Ruifeng fund bought the stock, the market value of Andon Health Co.Ltd(002432) held by Beixin Ruifeng fund is about 132 million yuan, and the current share price of Andon Health Co.Ltd(002432) is as high as 75.28 yuan per share. If Beixin Ruifeng fund does not cash in, the market value of Andon Health Co.Ltd(002432) held by this fund company will be as high as 1.484 billion, which also means that, Beixin Ruifeng fund company will make a profit of at least 1.3 billion in one stock, which is almost like pie in the sky for a mini fund company with a scale of less than 10 billion.
However, after the stock price achieved an amazing rise in a short time, the risk factors of the high stock price and the smooth implementation of orders also began to attract capital attention. On January 16, Andon Health Co.Ltd(002432) disclosed the abnormal fluctuation of stock trading and risk warning. It showed that during the execution of contracts and orders between the company’s U.S. subsidiaries and New York, Massachusetts and HHS (executed by the American ACC representative), the company was affected by changes in local epidemic situation, changes in policies, changes in the company’s supply chain capacity Under the influence of logistics and transportation risks, unpredictable or force majeure and other factors, there may be a risk that the contract or order can not be performed on schedule or in full.
Andon Health Co.Ltd(002432) also said that it should be noted that the U.S. government has the right to terminate the contract signed between the company’s U.S. subsidiary and U.S. HHS (executed by the U.S. ACC representative) at any time due to its own factors. There is uncertainty whether the contract can be fully implemented.
Obviously, it is difficult to determine whether the Beixin Ruifeng fund, which has already got on the bus, can really eat meat in front of ten times the shares. In addition, the relevant companies have just issued a risk warning announcement on order implementation, which may also increase the difficulty of fund cashing.
